Gonadotropin-Releasing Hormone

• 

  Subject Areas on Research

  • A mathematical model for LH release in response to continuous and pulsatile exposure of gonadotrophs to GnRH. 
  • A mathematical model quantifying GnRH-induced LH secretion from gonadotropes. 
  • A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. 
  • A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men. 
  • Acute and subacute effects of naturally occurring estrogens on luteinizing hormone secretion in the ovariectomized rat: Part 1. 
  • Acute and subacute effects of naturally occurring estrogens on luteinizing hormone secretion in the ovariectomized rat: Part 2. 
  • Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. 
  • Adjunctive leuprolide therapy does not improve cycle fecundity in controlled ovarian hyperstimulation and intrauterine insemination of subfertile women. 
  • Alterations in luteal phase progesterone and estradiol production after leuprolide acetate therapy before ovarian stimulation for in vitro fertilization. 
  • Amenorrhea: observations based on the analysis of luteinizing hormone-releasing hormone testing. 
  • Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer. 
  • Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. 
  • Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer. 
  • Anogenital distance at birth as a predictor of volume of the sexually dimorphic nucleus of the preoptic area of the hypothalamus and pituitary responsiveness in castrated adult rats. 
  • Are Small Reimbursement Changes Enough to Change Cancer Care? Reimbursement Variation in Prostate Cancer Treatment. 
  • Basic fibroblast growth factor regulates the conversion of pro-luteinizing hormone-releasing hormone (Pro-LHRH) to LHRH in immortalized hypothalamic neurons. 
  • Challenges to our understanding of endometriosis pain. 
  • Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study. 
  • Clinical characteristics of ovulation induction with human menopausal gonadotropins with and without leuprolide acetate in polycystic ovary syndrome. 
  • Clinical decision making regarding leiomyomata: what we need in the next millenium. 
  • Combination hormonal therapy: a reassessment within advanced prostate cancer. 
  • Combined antibody-high-performance liquid chromatography approach to assess prohormone processing. 
  • Combined impact of the number of pre-ovulatory oocytes and cryopreservation on IVF outcome. 
  • Construction and analysis of protein-protein interaction networks based on proteomics data of prostate cancer. 
  • Contemporary hormonal management of advanced prostate cancer. 
  • Cycle day, estrogen level, and lead follicle size: analysis of 27,790 in vitro fertilization cycles to determine optimal start criteria for gonadotropin-releasing hormone antagonist. 
  • Deficits in reproduction and pro-gonadotropin-releasing hormone processing in male Cpefat mice. 
  • Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database. 
  • Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. 
  • Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. 
  • Differential expression of gamma-aminobutyric acid receptors in immortalized luteinizing hormone-releasing hormone neurons. 
  • Differential secretion of proLHRH fragments in response to [K+], prostaglandin E2 and C kinase activation. 
  • Dose-response characteristics of neonatal exposure to genistein on pituitary responsiveness to gonadotropin releasing hormone and volume of the sexually dimorphic nucleus of the preoptic area (SDN-POA) in postpubertal castrated female rats. 
  • Early prostate cancer: the national results of radiation treatment from the Patterns of Care and Radiation Therapy Oncology Group studies with prospects for improvement with conformal radiation and adjuvant androgen deprivation. 
  • Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. 
  • Effect of neonatal diethylstilbestrol exposure on luteinizing hormone secretion following ketamine anesthesia and gonadotropin-releasing hormone in castrated postpubertal rats. 
  • Effect of neonatal diethylstilbestrol exposure on volume of the sexually dimorphic nucleus of the preoptic area of the hypothalamus and pituitary responsiveness to gonadotropin-releasing hormone in female rats of known anogenital distance at birth. 
  • Effect of suckling on the hypothalamic-pituitary axis in postpartum beef cows, independent of ovarian secretions. 
  • Effects of castration and chronic steroid treatments on hypothalamic gonadotropin-releasing hormone content and pituitary gonadotropins in male wild-type and estrogen receptor-alpha knockout mice. 
  • Effects of charcoal-extracted follicular fluid on reproductive function in postpartum cows. 
  • Effects of insulin-like growth factors I and II and insulin on the immortalized hypothalamic GTI-7 cell line. 
  • Effects of phytoestrogens on GnRH-induced luteinizing hormone secretion in ovariectomized rats. 
  • Effects of prenatal treatment with antiandrogens on luteinizing hormone secretion and sex steroid concentrations in adult spotted hyenas, Crocuta crocuta. 
  • Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. 
  • Endocrine therapy in metastatic breast cancer. 
  • Endometrial receptivities after leuprolide suppression and gonadotropin stimulation: histology, steroid receptor concentrations, and implantation rates. 
  • Endoscopic management of leiomyomata. 
  • Evaluation of pituitary gonadotropic function in men: value of luteinizing hormone-releasing hormone response versus basal luteinizing hormone level for discrimination of diagnosis. 
  • Evolution of therapeutic approaches with luteinizing hormone-releasing hormone agonists in 2003. 
  • Expression of candidate pro-GnRH processing enzymes in rat hypothalamus and an immortalized hypothalamic neuronal cell line. 
  • External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation. 
  • FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist. 
  • Follicular atresia associated with concurrent initiation of gonadotropin-releasing hormone agonist and follicle-stimulating hormone for oocyte recruitment. 
  • Functionally compromised CHD7 alleles in patients with isolated GnRH deficiency. 
  • Gonadotropin release in patients with androgen insensitivity. Testicular feminization syndrome. 
  • Gonadotropin releasing hormone stimulates calmodulin redistribution in rat pituitary. 
  • Gonadotropin-releasing hormone agonist overuse: urologists' response to reimbursement and characteristics associated with persistent overuse. 
  • Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer. 
  • Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. 
  • Gonadotropin-releasing hormone neuronal cell lines. 
  • High Peak Estradiol Predicts Higher Miscarriage and Lower Live Birth Rates in High Responders Triggered with a GnRH Agonist in IVF/ICSI Cycles. 
  • High Peak Estradiol/Mature Oocyte Ratio Predicts Lower Clinical Pregnancy, Ongoing Pregnancy, and Live Birth Rates in GnRH Antagonist Intracytoplasmic Sperm Injection Cycles. 
  • Hormonal characteristics of free-ranging female lions (Panthera leo) of the Serengeti Plains and Ngorongoro Crater. 
  • Hormone naïve prostate cancer: predicting and maximizing response intervals. 
  • Hydrolysis by somatic angiotensin-I converting enzyme of basic dipeptides from a cholecystokinin/gastrin and a LH-RH peptide extended at the C-terminus with gly-Arg/Lys-arg, but not from diarginyl insulin. 
  • Hypothalamic and pituitary function in hypogonadotropic hypogonadism. 
  • Hypothalamic astrocytes respond to transforming growth factor-alpha with the secretion of neuroactive substances that stimulate the release of luteinizing hormone-releasing hormone. 
  • Immortalized hypothalamic gonadotropin-releasing hormone neurons. 
  • Immortalized hypothalamic luteinizing hormone-releasing hormone (LHRH) neurons: a new tool for dissecting the molecular and cellular basis of LHRH physiology. 
  • Impact of leuprolide acetate on the response to follicular stimulation for in vitro fertilization in patients with normal basal gonadotropin levels. 
  • Implantation and pregnancy rates in relation to oestradiol and progesterone profiles in cycles with and without the use of gonadotrophin-releasing hormone agonist suppression. 
  • In-vitro fertilization and embryo transfer in patients with endometriosis: impact of a gonadotrophin releasing hormone agonist. 
  • Inhibition of growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos oncogene expression by bombesin antagonists. 
  • Intrinsic pulsatile secretory activity of immortalized luteinizing hormone-releasing hormone-secreting neurons. 
  • Lack of effects from 2000-Hz magnetic fields on mammary adenocarcinoma and reproductive hormones in rats 
  • Late ovarian hyperstimulation syndrome after controlled ovarian stimulation in a woman with systemic lupus erythematosus and lupus nephritis. 
  • Luteal supplementation in in vitro fertilization: more questions than answers. 
  • Management of metastatic prostatic cancer. 
  • Mathematical modeling of perifusion cell culture experiments on GnRH signaling. 
  • Mechanism of action of hypothalamic hormones in the anterior pituitary gland and specific modulation of their activity by sex steroids and thyroid hormones. 
  • Metabolism of pro-luteinizing hormone-releasing hormone in immortalized hypothalamic neurons. 
  • Microcephaly, hypergonadotropic hypogonadism, short stature, and minor anomalies: a new syndrome. 
  • Mild/minimal stimulation for in vitro fertilization: an old idea that needs to be revisited. 
  • Minimal ovarian hyperstimulation for in vitro fertilization using sequential clomiphene citrate and gonadotropin with or without the addition of a gonadotropin-releasing hormone antagonist. 
  • Morphological characterization of immortalized hypothalamic neurons synthesizing luteinizing hormone-releasing hormone. 
  • NMDA and nitric oxide act through the cGMP signal transduction pathway to repress hypothalamic gonadotropin-releasing hormone gene expression. 
  • Neural and glial-mediated effects of growth factors acting via tyrosine kinase receptors on luteinizing hormone-releasing hormone neurons. 
  • Neuroendocrine control of follicle-stimulating hormone (FSH) secretion: II. Is follistatin-induced suppression of FSH secretion mediated via changes in activin availability and does it involve changes in gonadotropin-releasing hormone secretion? 
  • New data, new paradigms for treating prostate cancer patients--VI: novel hormonal therapy approaches. 
  • Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. 
  • Orchidectomy induces temporal and regional changes in the synthesis and processing of the LHRH prohormone in the rat brain. 
  • Ovarian hyperstimulation in polycystic ovary syndrome during therapy with leuprolide acetate. 
  • Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. 
  • Ovarian stimulation for in vitro fertilization using pure follicle-stimulating hormone with and without gonadotropin-releasing hormone agonist in high-responder patients. 
  • Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. 
  • Pathology and pathophysiology of uterine smooth-muscle tumors. 
  • Performance of cryopreserved pre-embryos obtained in in vitro fertilization cycles with or without a gonadotropin-releasing hormone agonist. 
  • Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer. 
  • Predictors and implications of estradiol rise after gonadotropin-releasing hormone antagonist initiation during in vitro fertilization cycles. 
  • Predictors of Time to Metastasis in Castration-resistant Prostate Cancer. 
  • Prevention of the polycystic ovarian phenotype and characterization of ovulatory capacity in the estrogen receptor-alpha knockout mouse. 
  • Pro-GnRH processing. 
  • Processing of the luteinizing hormone-releasing hormone precursor in the preoptic area and hypothalamus of the rat. 
  • Progesterone levels on the day of human chorionic gonadotropin administration in cycles with gonadotropin-releasing hormone agonist suppression are not predictive of pregnancy outcome. 
  • Progesterone levels on the day of human chorionic gonadotropin do not predict pregnancy outcome from the transfer of fresh or cryopreserved embryos from the same cohort. 
  • Prostate cancer: diagnosis, treatment, and experience at one tertiary-care military medical center, 1989 and 1994. 
  • Prostate cancer: making the switch from LHRH antagonist to LHRH agonist. 
  • Rapid behavioral and genomic responses to social opportunity. 
  • Regulation of gonadotropin-releasing hormone by protein kinase-A and -C in immortalized hypothalamic neurons. 
  • Regulation of gonadotropin-releasing hormone secretion by cannabinoids. 
  • Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. 
  • Reproductive hormones in aging men. II. Basal pituitary gonadotropins and gonadotropin responses to luteinizing hormone-releasing hormone. 
  • Role of aromatase in endometrial disease. 
  • Role of gonadotropin-releasing hormone pulse frequency in differential regulation of gonadotropins in the gilt. 
  • Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. 
  • Stimulation protocols for patients with "atypical response". 
  • Suppression and flare regimens of gonadotropin-releasing hormone agonist. Use in women with different basal gonadotropin values in an in vitro fertilization program. 
  • Suppression of male-specific cytochrome P450 2c and its mRNA by 3,4,5,3',4',5'-hexachlorobiphenyl in rat liver is not causally related to changes in serum testosterone. 
  • Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. 
  • Targeted disruption of the mouse gene encoding steroidogenic acute regulatory protein provides insights into congenital lipoid adrenal hyperplasia. 
  • Targeting the androgen receptor--theory and practice. 
  • Testosterone administration suppresses adiponectin levels in men. 
  • Testosterone rapidly increases neural reactivity to threat in healthy men: a novel two-step pharmacological challenge paradigm. 
  • Testosterone selectively influences protein kinase-C-coupled secretion of proluteinizing hormone-releasing hormone-derived peptides. 
  • The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data. 
  • The bi-modal effects of estradiol on gonadotropin synthesis and secretion in female mice are dependent on estrogen receptor-alpha. 
  • The effect of leuprolide acetate on ovulation induction with human menopausal gonadotropins in polycystic ovary syndrome. 
  • The effect of neonatal exposure to DES and o,p'-DDT on pituitary responsiveness to GnRH in adult castrated rats. 
  • The effect of neonatal exposure to diethylstilbestrol, coumestrol, and beta-sitosterol on pituitary responsiveness and sexually dimorphic nucleus volume in the castrated adult rat. 
  • The effect of neonatal exposure to diethylstilbestrol, genistein, and zearalenone on pituitary responsiveness and sexually dimorphic nucleus volume in the castrated adult rat. 
  • The effect of prenatal exposure to the phytoestrogen genistein on sexual differentiation in rats. 
  • The luteal phase in polycystic ovary syndrome during ovulation induction with human menopausal gonadotropin with and without leuprolide acetate. 
  • The nuclear receptor steroidogenic factor 1 is essential for the formation of the ventromedial hypothalamic nucleus. 
  • The rejuvenating effects of leuprolide acetate on the aged baboon's thymus. 
  • The role of primary androgen deprivation therapy in localized prostate cancer. 
  • Transdermal iontophoretic delivery of luteinizing hormone releasing hormone (LHRH): effect of repeated administration. 
  • Transdermal iontophoretic peptide delivery: in vitro and in vivo studies with luteinizing hormone releasing hormone. 
  • Transfer of cryopreserved-thawed pre-embryos in a cycle using exogenous steroids without prior gonadotrophin-releasing hormone agonist suppression yields favourable pregnancy results. 
  • Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer. 
  • Twenty-five year evolution of medical hormonal therapy for prostate cancer. 
  • Utility of LHRH antagonists for advanced prostate cancer. 
  • Value of suppression with a gonadotropin-releasing hormone agonist prior to gonadotropin stimulation for in vitro fertilization. 
  • alpha(1)-adrenergic receptors mediate LH-releasing hormone secretion through phospholipases C and A(2) in immortalized hypothalamic neurons. 
  • p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).